Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for RAS-MAPK Targeted Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SHOC2/Sur-8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Protein | SHOC2 Recombinant Protein (WT & M173I Mutant) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. HEK293 expressed for native conformation. Optimized for PPI assays. |
View SHOC2 Products |
| Gene Delivery | SHOC2 Lentivirus / Promise-ORF Particles Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. Ideal for synthetic lethality screening and degrader tracking. |
View SHOC2 Products |
| Benchmark Ab | Anti-SHOC2 Reference Antibody (Monoclonal) Recombinant rabbit mAb, Sequence Verified. Suitable for WB, Co-IP, and target engagement assays. |
View SHOC2 Products |
| Validator | SHOC2 siRNA Set (3 target-specific sequences) For knockdown verification and functional validation in RAS-mutant models. |
View SHOC2 Products |
| Related Target A | KRAS Upstream oncogenic driver; SHOC2 inhibition provides synthetic lethality in KRAS-mutant cancers. |
View KRAS Products |
| Related Target B | PPP1CA (PP1c) Forms the ternary SMP complex (SHOC2-MRAS-PP1C) required for RAF dephosphorylation. |
View PPP1CA Products |
| Related Target C | MRAS Essential binding partner for SHOC2-mediated pathway activation. |
View MRAS Products |
| Related Target D | RAF1 Direct binding partner in RAS-RAF-MEK axis. Critical for PPI assay development. |
View RAF1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex (SMP) Reconstitution In Vitro | High-Purity (>95%) recombinant components (SHOC2, MRAS, PP1C) strictly sequence verified for SPR/BLI. HEK293 expressed ensures native folding. |
| Intracellular Target Engagement Validation | High-titer Lentivirus vectors enabling stable reporter cell line construction for PROTAC/degrader tracking. |
| M173I Mutant Modeling (Noonan Syndrome/Resistance) | M173I Mutant Protein available, Sequence Verified, Soluble expression maintained. Essential for mutant vs WT selectivity assays. |
| PPI Specificity (RAF1 vs PP1 binding discrimination) | Homolog Panel Proteins (RAF1, BRAF, PPP1CA) strictly verified for counter-screening. |
| Lack of Reliable Controls | Sequence-verified reference antibodies included to ensure reproducible western blot / IP data. |
| False Positives in Viability Screens | Endotoxin-controlled (<1EU/ug) reagents and validated siRNA sets for orthogonal specificity checks. |
Live SHOC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SHOC2 therapeutics is intensifying as researchers look beyond direct KRAS inhibition. SHOC2 acts as a critical scaffolding protein, forming a complex with MRAS and PP1C to dephosphorylate and activate RAF kinases. Because SHOC2 deletion is synthetically lethal in RAS-driven tumors, major players are shifting focus from traditional kinase inhibitors to Protein-Protein Interaction (PPI) inhibitors and Targeted Protein Degradation (PROTACs/Molecular Glues). As first-generation KRAS G12C therapies encounter acquired resistance in the clinic, the next wave of R&D is targeting the SHOC2 node as a universal combination partner to durably suppress the MAPK pathway and bypass upstream resistance mechanisms. Additionally, SHOC2-mediated RAF reactivation represents a key bypass mechanism to RAF/MEK inhibitor resistance, driving demand for high-fidelity PPI assays and mutant protein panels for preclinical validation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PPI Inhibitors (Small Molecule) | Revolution Medicines, Erasca, Academic Consortia | RAS-mutated Solid Tumors (NSCLC, Pancreatic, CRC) | Ternary Complex SPR Assay & Full-length SHOC2+RAF1/PP1 Protein Pairs |
| PROTACs / Molecular Glues | BridGene Biosciences, Arvinas, Undisclosed Early Stage | Pan-KRAS & MAPK-driven Malignancies; Solid Tumors (Synthetic Lethal) | Target Degradation Assays & Ternary Complex Formation Assay (high purity components) |
| Antisense Oligonucleotide | Rare Disease Programs | Noonan Syndrome (M173I) | Mutant vs WT Selectivity Assay (need M173I protein) |
| Combination Therapy (Small Mol) | Various Big Pharma | KRAS-Inhibitor Refractory Cancers | Synthetic Lethality Screening & Pathway cascade analysis (pMEK/pERK) |